<DOC>
	<DOCNO>NCT00971659</DOCNO>
	<brief_summary>This study investigate 4-week adjunctive therapy either GLP-1 analog ( exenatide ) , DPP-4 inhibitor ( sitagliptin ) , give basal insulin analog ( insulin glargine ) , effect blood glucose control , versus insulin glargine alone active comparator type 2 diabetes .</brief_summary>
	<brief_title>Adjunctive Therapy Exenatide Sitagliptin Insulin Glargine Type 2 Diabetes</brief_title>
	<detailed_description>Due different mechanism action long-acting insulin analog insulin glargine GLP-1 analog ( exenatide ) DPP-4-inhibitor ( sitagliptin ) , could promise approach combine insulin glargine either exenatide sitagliptin optimum control fast postprandial blood glucose value . Thus , present study influence either exenatide sitagliptin 4-week adjunctive therapy basal insulin ( insulin glargine ) investigate versus insulin glargine alone active comparator subject type 2 diabetes . Preexisting metformin continue , sulfonylurea , , stop . In particular , effect postprandial blood glucose excursion follow ingestion standard breakfast , assess 4 week treatment , effect mean daily blood glucose , self-measured 7-point profile , percentage subject reach ADA treatment goal ( HbA1c &lt; 7.0 % ) end treatment , fast lipid profile , HOMA index , weight , hypoglycemic episode general safety assess . The study consist screen visit , 4-8 week ( depend pre-treatment ) run-in period , 4-week treatment period , follow-up visit . There weekly visit site twice weekly telephone contact .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>male female subject age 35 70 year , inclusive type 2 diabetes duration &gt; 6 month &lt; 10 year least 3 month : treatment solely long intermediateacting insulin formulation ( insulin glargine , insulin detemir , NPH insulin ) without stable dose metformin treatment solely stable dose metformin combination stable dos metformin plus sulfonylureas HbA1c &gt; =7.0 % &lt; =10.0 % treat antihypertensive lipid lower agent , treatment regimen stable 3 month prior study start write informed consent history presence cancer clinically relevant disease chronic heart failure NYHA class III IV , unstable angina pectoris myocardial infarction within previous 6 month recurrent hypoglycemia abnormal lab test screen ( ALAT and/or ASAT &gt; =3 time ULN ) , creatinine &gt; 1.6 mg/dL male &gt; 1.4 mg/dL female clinically relevant ECG finding screen treatment rapidacting insulin mixed insulin formulation previous 3 month treatment OHA metformin metformin plus sulfonylureas previous 3 month systemic topical treatment drug know influence glucose metabolism</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>type 2 diabetes</keyword>
</DOC>